Press release from Companies

Published: 2020-06-30 18:27:29

Scandion Oncology: Scandion Oncology co-founders extend lock-up period

Scandion Oncology A/S ("Scandion Oncology") announces that its two co-founders, CEO Nils Brünner and CSO Jan Stenvang, have extended the lock-up period for their Scandion Oncology shares with an additional three months (until October 1, 2020). In total, the lock-up agreements correspond to approximately 13 percent of the votes and capital in Scandion Oncology.

CEO Nils Brünner and CSO Jan Stenvang have signed and prolonged the lock-up agreements for their shares with three months. The two co-founders commit to retain 90 percent of their holdings in the company until October 1, 2020. The following parties have updated their lock-up agreements:

Nils Brünner                     1.083.240*

* Privately and through the company TIMPCO NB ApS

Jan Stenvang                     1.391.064

Total:                    2.474.304

Nils Brünner, CEO of Scandion Oncology says:

"We have no intention to sell any Scandion Oncology shares now. We are looking forward to the near future where the first clinical data with SCO-101 in combination with chemotherapy in drug resistant colorectal cancer patients will be presented. We see Scandion Oncology as a growth company with strong potential to reach its goals and planned milestones."

For further information regarding Scandion Oncology, please contact:

Nils Brünner, CEO

Phone: +45 26 14 47 08

E-mail: nb@scandiononcology.com

This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on June 30, 2020.

Scandion Oncology A/S is a biotechnology company that addresses and targets one of the greatest challenges in modern oncology - the effective treatment of cancer which contains chemotherapy-resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro studies, SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company's leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018. For further information, please see: www.scandiononcology.com.

Läs mer hos Cision
Read more about Scandion Oncology

Subscription